Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia

Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatini...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobash, Philip T., Guddati, Achuta K., Kota, Vamsi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265745/
https://www.ncbi.nlm.nih.gov/pubmed/32518550
http://dx.doi.org/10.1159/000506895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265745/
https://www.ncbi.nlm.nih.gov/pubmed/32518550
http://dx.doi.org/10.1159/000506895

Ejemplares similares